|Systematic (IUPAC) name|
(6aR,9R)-N-((2R,5S,10aS,10bS)- 5-benzyl-10b-hydroxy-2-methyl- 3,6-dioxooctahydro-2H-oxazolo[3,2-a] pyrrolo[2,1-c]pyrazin-2-yl) -7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg] quinoline-9-carboxamide
Intravenous: 100% ,|
Intramuscular: 47% ,
Oral: <1%  (Enhanced by co-administration of caffeine )
|Biological half-life||2 hours |
|Excretion||90% biliary |
|ATC code||N02CA02 (WHO)|
|Molar mass||581.66 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Ergotamine is an ergopeptine and part of the ergot family of alkaloids; it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several neurotransmitters, and has biological activity as a vasoconstrictor. It is used medicinally for treatment of acute migraine attacks (sometimes in combination with caffeine), and to induce childbirth and prevent post-partum haemorrhage. It was first isolated from the ergot fungus by Arthur Stoll at Sandoz in 1918 and marketed as Gynergen in 1921. 
Mechanism of action
The mechanism of action of ergotamine is complex. The molecule shares structural similarity with neurotransmitters such as serotonin, dopamine, and epinephrine and can thus bind to several receptors acting as an agonist. The anti-migraine effect is due to constriction of the intracranial extracerebral blood vessels through the 5-HT1B receptor, and by inhibiting trigeminal neurotransmission by 5-HT1D receptors. Ergotamine also has effects on the dopamine and norepinephrine receptors. It is its action on the D2 dopamine and 5-HT1A receptors that can cause some side effects. 
Ergotamine is a secondary metabolite (natural product) and the principal alkaloid produced by the ergot fungus, Claviceps purpurea, and related fungi in the family Clavicipitaceae. Its biosynthesis in these fungi requires the amino acid L-tryptophan and dimethylallyl diphosphate. These precursor compounds are the substrates for the enzyme, dimethylallyl-tryptophan (DMAT) synthase, catalyzing the first step in ergot alkaloid biosynthesis, i.e., the prenylation of L-tryptophan. Further reactions, involving methyltransferase and oxygenase enzymes, yield the ergoline, lysergic acid. Lysergic acid (LA) is the substrate of lysergyl peptide synthetase, a nonribosomal peptide synthetase, which covalently links LA to the amino acids, L-alanine, L-proline, and L-phenylalanine. Enzyme-catalyzed or spontaneous cyclizations, oxygenations/oxidations, and isomerizations at selected residues precede, and give rise to, formation of ergotamine.
Ergotamine produces vasoconstriction peripherally as well as damages the peripheral epithelium. In high doses ergotamine is conducive to vascular stasis, thrombosis and gangrene. It can increase uterine contractivity and occasionally is used therapeutically immediately post-partum to decrease uterine bleeding.See also ergometrine.
Ergotamine continues to be prescribed for migraines.
Ergotamine is also a precursor of LSD.
Ergotamine is associated with adverse effects that are significantly more severe than the effects of the triptans. These side effects, along with a decreased effectiveness compared to the triptans, explain why ergotamine is a rarely used abortive drug for the treatment of migraines. The side effects include GI tract irritation, tingling, angina, contraction of the uterus, damage to the endothelium, vasoconstriction, drowsiness, dizziness and rebound headache. The risk of ergotamine's side effects becomes greater when taken with other drugs that inhibit its metabolism.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
- Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1983; 30: 331–4.
- Tfelt-Hansen P, Johnson ES. Ergotamine. In: Olesen J, Tfelt-Hansen P, Welch KM, editors. The headaches. New York: Raven Press; 1993. p. 313–22.
- Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983; 16: 695–9.
- AJ Giannini, AE Slaby. Drugs of Abuse. Oradell, NJ, Medical Economics Books, 1989.
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000). "Ergotamine in the acute treatment of migraine: a review and European consensus". Brain. 123: 9–18. doi:10.1093/brain/123.1.9. PMID 10611116.
- Schardl CL, Panaccione DG, Tudzynski P (2006). "Ergot alkaloids--biology and molecular biology". Alkaloids Chem. Biol. 63: 45–86. doi:10.1016/S1099-4831(06)63002-2. PMID 17133714.
- AJ Giannini. Biological Foundations of Clinical Psychiatry. Oradell, NJ. Medical Economics Puclishing Co., 1986.